Cargando…
Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients
Pemphigus is an autoimmune mucocutaneous blistering disease caused by autoantibodies against desmogleins. Rituximab effectively treats pemphigus by inducing remission and rapidly reducing corticosteroid dosage. In Korea, the high cost of rituximab had been a burden until the National Health Insuranc...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379325/ https://www.ncbi.nlm.nih.gov/pubmed/35983042 http://dx.doi.org/10.3389/fimmu.2022.932909 |